News & Media

Feb. 18th

QIAGEN becomes exclusive partner for bioinformatics research applications based on ARESdb and AREStools
Partnership intends to create a community platform for antimicrobial resistance research

Feb. 04th

Submission for Unyvero HPN Cartridge to Chinese regulatory authority NMPA includes U.S. and EU data
Leverages recent changes in regulation allowing submission of foreign data
Further collection of clinical data in China planned to support market access and adoption

Jan. 30th

HPN Cartridge approved in Malaysia; HPN, BCU Cartridges approved in Thailand
Further commercial roll-out of Unyvero in ASEAN region by partner Acumen Research Laboratories facilitated
Near-term Chinese NMPA submission of Unyvero HPN expected

News Archives

Dec 18 – Curetis’ Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance

Dec 13 – Curetis Sharpens Focus on Near-Term Strategic Value Drivers

Nov 23 – Curetis Announces Financial Results for the First Nine Months of 2018

Nov 23 – Curetis Accelerates 510(k) Submission Preparation for Unyvero

Oct 11 – Curetis, Beijing Clear Biotech Expand Strategic Collaboration for Unyvero in Greater China

Oct 02 – Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes

Sep 28 – Curetis Publishes Interim Report for the First Half-Year 2018

Sep 17 – Curetis To Attend Key Investor and Scientific Conferences In The Fourth Quarter 2018

Sep 04 – Curetis’ Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test

Aug 14 – Curetis Announces Change in Curetis USA Inc. Management

Aug 14 – Curetis Announces Financial Results for the First Six Months of 2018

Aug 07 – Curetis to Report its Half-Year Results 2018 on August 14, 2018

Aug 07 – Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets

Jul 31 – Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program

Jun 21 – Curetis Reports Results of the Annual General Meeting Held on June 21, 2018

Jun 12 – Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2018

Jun 07 – Curetis Launches Unyvero System and LRT Cartridge for Lower Respiratory Tract Infections in the U.S.

May 18 – Curetis Publishes Business and Financial Update for the First Quarter 2018

May 09 – Curetis to Hold Annual General Shareholders’ Meeting on June 21, 2018

Apr 30 – Curetis Announces Change of the Composition of Its Supervisory Board

Apr 30 – Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018

Apr 27 – Curetis to Raise EUR 4.1 Million in Equity Offering with Access to Additional USD 10 million in Equity Over 36 Months

Apr 23 – Curetis to Publish its 2017 Annual Results on April 30, 2018

Apr 19 – Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018

Apr 18 – Curetis: Novel Products and Study Data to be Presented at ECCMID 2018

Apr 11 – Curetis Establishes U.S. Scientific Advisory Board

Apr 04 – Curetis to Hold Investor Conference Call with Webcast on U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge today

Apr 04 – Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority

Apr 03 – Curetis Receives U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge

Mar 26 – Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018

Mar 14 – Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology

Mar 06 – Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley

Feb 06 – Curetis Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test

Feb 05 – Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017

Jan 10 – Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

Jan 08 – Curetis Expects Near-Term FDA Decision on De Novo Request

Dec 19 – Curetis To Attend Key Investor and Scientific Conferences In The First Quarter 2018

Nov 16 – Curetis Publishes Business and Financial Update for the First Nine Months of 2017

Oct 23 – Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge

Oct 06 – Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017

Sep 12 – MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics

Aug 16 – Curetis Announces Financial Results for the First Six Months of 2017

Aug 16 – Curetis Announces Management Board Changes

Aug 15 – Curetis Partners with Biotest to support academic PEPPER Pentaglobin® Peritonitis Trial with Unyvero IAI Application

Aug 04 – Curetis to Report its Half-Year Results 2017 on August 16, 2017

Jul 07 – Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017

Jun 26 – “GEAR – Predicting Antibiotic Resistances with Genetic Data” Succeeds in Competition “Landmarks in the Land of Ideas”

Jun 23 – Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017

May 24 – Curetis Provides Business and Financial Update for the First Quarter 2017

May 24 – Curetis Provides Update on Unyvero LRT FDA 510(k) Submission

May 08 – Curetis to Hold Annual General Shareholders’ Meeting on June 23, 2017

Apr 27 – Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits

Apr 20 – Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking

Apr 12 – Curetis Expands Supervisory and Medical Advisory Boards

Apr 12 – Curetis Reports Full-Year 2016 Financial Results and Updates 2017 Guidance

Apr 10 – Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe

Apr 06 – Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing

Apr 04 – Curetis to Publish its Annual Results 2016 on April 12, 2017

Mar 29 – Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017

Mar 08 – Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech

Jan 31 – Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers

Jan 05 – Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge

Jan 04 – Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017

Jan 04 – Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections

Dec 13 – Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec

Dec 13 – Curetis to host Conference Call and Webcast on EIB Debt Financing Facility and Gyronimo Asset Acquisition

Dec 12 – #investEU – Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform

Nov 18 – Curetis Publishes Business and Financial Update for the First Nine Months 2016

Oct 25 – Curetis Announces Positive Top Line Data from U.S. FDA Trial

Oct 04 – Curetis to Present at Several Investor and Scientific Conferences in the Fourth Quarter 2016

Sep 07 – Curetis to host conference call and webcast on GEAR acquisition

Sep 07 – Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens

Sep 06 – Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge

Aug 19 – Curetis Reports Financial Results for the First Six Months of 2016

Aug 01 – Curetis to Report its Half-Year Results 2016 on August 19, 2016

Jul 05 – Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary

Jul 01 – Curetis Announces Participation in Clinical, Scientific and Investor Meetings in the Third Quarter 2016

Jun 28 – Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections

Jun 17 – Curetis Reports Results of the Annual Shareholder Meeting Held on June 16, 2016

Jun 15 – Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge

Jun 06 – Curetis and Axonlab sign multi-market European distribution agreement

May 20 – Curetis Publishes First Quarter 2016 Business and Financial Update

May 02 – Curetis shall hold its Annual General Shareholders’ Meeting on June 16, 2016

Apr 12 – Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance

Mar 24 – Curetis Announces Participation in Several Investor and Industry Conferences in Q2-2016

Mar 24 – Curetis to Publish its Annual Results 2015 on April 12, 2016

Mar 23 – Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016

Feb 23 – Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge

Feb 03 – Curetis Expands Commercial Team

Jan 11 – Curetis Establishes Medical Advisory Board with Internationally Renowned Experts

Jan 05 – Curetis Announces Participation in Several Investor and Industry Conferences

Upcoming Events

Paris, France
Jan 23-25, 2019
Bremen, Germany
February 20 to 22, 2019
Amsterdam, Netherlands
April 13-16th 2019
Savannah, GA
Booth #104
May 5-8, 2019
San Francisco, CA
Booth #1236
June 20-24, 2019